Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q2 FY25 results · Jul–Sep 2024
Dr. Lal Path Labs reported revenue from operations of ₹660.20 crore (up 9.8% from Q2 FY24) and net profit of ₹130.80 crore (up 18.2% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 660.20 | 601.30 | +9.8% | 601.90 | +9.7% |
| Other income | 21.90 | 18.10 | +21.0% | 20.60 | +6.3% |
| Total income | 682.10 | 619.40 | +10.1% | 622.50 | +9.6% |
| Profit before tax | 183.10 | 152.20 | +20.3% | 149.90 | +22.1% |
| Net profit for the period | 130.80 | 110.70 | +18.2% | 107.80 | +21.3% |
| Attributable to shareholders of the company | 129.20 | 109.30 | +18.2% | 106.40 | +21.4% |
| EPS, basic (₹) | 15.52 | 13.16 | +17.9% | 12.79 | +21.3% |
| Net margin (%) | 19.8 | 18.4 | 17.9 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 583.90 | 531.70 | +9.8% | 534.50 | +9.2% |
| Other income | 22.00 | 14.10 | +56.0% | 28.80 | −23.6% |
| Total income | 605.90 | 545.80 | +11.0% | 563.30 | +7.6% |
| Profit before tax | 183.30 | 150.90 | +21.5% | 161.00 | +13.9% |
| Net profit for the period | 135.20 | 113.00 | +19.6% | 122.90 | +10.0% |
| EPS, basic (₹) | 16.24 | 13.60 | +19.4% | 14.76 | +10.0% |
| Net margin (%) | 23.2 | 21.3 | 23.0 |
Consolidated
- Filed with BSE
- 24 Oct 2024, 12:57 IST
- Board meeting
- 23 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Oct 2024, 12:57 IST
- Board meeting
- 23 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE